Skip to main content

Zealand Pharma Virtual R&D Day Materials Now Available with Live Q&A Session on March 5, 2021

Written by Customer Service on . Posted in Public Companies.

Company announcement – No. 10 / 2021Zealand Pharma Virtual R&D Day Materials Now Available with Live Q&A Session on March 5, 2021Prerecorded materials now available on Zealand’s websiteCopenhagen, DK and Boston, MA, March 4, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL), a biotechnology company focused on the discovery, development, and commercialization of innovative peptide-based medicines, will host a live Q&A session on Friday, March 5, 2021 at 4:00 p.m. CET (10:00 a.m. ET) as part of its virtual R&D day for analysts and investors.A prerecorded session discussing Zealand’s development pipeline and five-year R&D strategy are now available on the “R&D Day” page of the Company’s website at https://www.zealandpharma.com/rddaymaterials. The live Q&A session to be hosted on March 5 can be found on the same web page, and a replay of the webcast will be archived on the Company’s website following the presentation.To dial in to the live Q&A session to ask a question, please use the following numbers:
Agenda & Presenters:Welcome
Emmanuel Dulac, President and Chief Executive OfficerZealand Today and 2025 Ambition
 Emmanuel DulacR&D Focus and Strategy
 Adam Steensberg, Chief Medical OfficerMetabolic Portfolio
 Danilo Verge, Head of Global Medical AffairsZealand Peptide Platform and Ambition for Accelerated Innovation
 Rie Schultz Hansen, Vice President, Discovery & InnovationGI/Inflammation Portfolio
Adam SteensbergClosing Remarks
Adam Steensberg / Emmanuel Dulac# # #About Zealand Pharma A/S 
Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery, development, and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.Zealand Pharma was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com.  Forward-Looking StatementThe above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.For further information, please contact: Zealand Pharma Investor Relations
Maeve Conneighton
Argot Partners
investors@zealandpharma.comZealand Pharma Media Relations 
David Rosen 
Argot Partners
media@zealandpharma.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.